Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

DYADIC INTERNATIONAL INC (DYAI) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

DYADIC INTERNATIONAL INC (DYAI), most recent 12 months reported: revenue $3.8M, net loss $7.62M. Latest balance sheet on file: liquid cash $3.11M, total debt $5.04M, net cash -$1.93M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): DBV Technologies S.A. · Prime Medicine, Inc. · OCUGEN, INC. · CURIS, INC. · Aligos Therapeutics, Inc. · Humacyte, Inc. · SCINAI IMMUNOTHERAPEUTICS LTD. · INHIBRX BIOSCIENCES, INC.

Stock screener

Watchlist